Progress in the diagnosis and treatment of severe pediatric Mycoplasma pneumoniae pneumonia
10.3760/cma.j.cn101070-20230715-00006
- VernacularTitle:儿童重症肺炎支原体肺炎的诊治进展
- Author:
Heng WANG
1
;
Jinrong LIU
;
Shunying ZHAO
Author Information
1. 国家儿童医学中心，首都医科大学附属北京儿童医院呼吸二科，北京 100045
- Keywords:
Mycoplasma pneumoniae pneumonia;
Macrolide resistance;
Severe cases;
Typing;
Targeted therapy;
Child
- From:
Chinese Journal of Applied Clinical Pediatrics
2023;38(11):842-845
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, the number of severe and drug-resistant Mycoplasma pneumoniae pneumonia (MPP) in school-aged children in East Asian countries is on the rise, especially in China.Pediatric MPP is a heterogeneous disease.Some MPP children have a self-limited progression after infection, while some suffer an aggravated and prolonged course of disease.The sequelae of airway occlusion leads to the declines of lung function and quality of life.Although a series of nationally epidemiological data on pediatric MPP in China are scant, pediatric MPP should be regarded as the highly concerned main respiratory disease of school-aged children due to the large population of children in China and the long-term effects of MPP-induced airway occlusion.This article briefly reviews the correlation between Mycoplasma pneumoniae resistance and severe MPP, as well as the classification and treatment of MPP.
